- Home
- RDAGU vs RARE Comparison
RDAGU vs RARE Comparison
Compare RDAGU & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDAGU
- RARE
- Stock Information
- Founded
- RDAGU N/A
- RARE 2010
- Country
- RDAGU
- RARE United States
- Employees
- RDAGU N/A
- RARE 1294
- Industry
- RDAGU
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- RDAGU
- RARE Health Care
- Exchange
- RDAGU NYSE
- RARE Nasdaq
- Market Cap
- RDAGU N/A
- RARE 3.3B
- IPO Year
- RDAGU N/A
- RARE 2014
- Fundamental
- Price
- RDAGU $10.26
- RARE $35.56
- Analyst Decision
- RDAGU
- RARE Strong Buy
- Analyst Count
- RDAGU 0
- RARE 17
- Target Price
- RDAGU N/A
- RARE $92.29
- AVG Volume (30 Days)
- RDAGU N/A
- RARE 1.0M
- Earning Date
- RDAGU N/A
- RARE 05-06-2025
- Dividend Yield
- RDAGU N/A
- RARE N/A
- EPS Growth
- RDAGU N/A
- RARE N/A
- EPS
- RDAGU N/A
- RARE N/A
- Revenue
- RDAGU N/A
- RARE $590,689,000.00
- Revenue This Year
- RDAGU N/A
- RARE $18.68
- Revenue Next Year
- RDAGU N/A
- RARE $28.74
- P/E Ratio
- RDAGU N/A
- RARE N/A
- Revenue Growth
- RDAGU N/A
- RARE 33.46
- 52 Week Low
- RDAGU N/A
- RARE $29.59
- 52 Week High
- RDAGU N/A
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- RDAGU N/A
- RARE 47.35
- Support Level
- RDAGU N/A
- RARE $33.48
- Resistance Level
- RDAGU N/A
- RARE $36.22
- Average True Range (ATR)
- RDAGU 0.00
- RARE 1.34
- MACD
- RDAGU 0.00
- RARE -0.08
- Stochastic Oscillator
- RDAGU 0.00
- RARE 40.66
About RDAGU REPUBLIC DIGITAL ACQUISITION CO UNI UNITS 1 CL A SHS &1/2 WT
Republic Digital Acquisition Co is a blank check company.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.